Table 1 Baseline characteristics of the study population
Variables | HCM (n = 50) | Control (n = 30) | p value |
|---|---|---|---|
Age, y | 51.2 ± 14.1 | 49.3 ± 10.8 | 0.968 |
Female, n (%) | 25 (50.0) | 14 (46.7) | 0.407 |
Asymmetric septal hypertrophy | 48 (96 %) | / | / |
Apical hypertrophy | 2 (4 %) | / | / |
LVOT obstruction | 32 (64 %) | / | / |
Systolic blood pressure, mmHg | 120.3 ± 15.2 | 119.4 ± 16.9 | 0.561 |
Diastolic blood pressure, mmHg | 72.8 ± 10.9 | 71.7 ± 11.5 | 0.838 |
Heart rate, bpm | 72.9 ± 11.3 | 76.9 ± 10.4 | 0.086 |
Body surface area, m2 | 1.69 ± 0.20 | 1.63 ± 0.31 | 0.989 |
Body mass index, kg/ m2 | 24.8 ± 3.1 | 23.5 ± 4.3 | 0.893 |
Hemoglobin, g/L | 135.5 ± 17.4 | 133.9 ± 19.0 | 0.865 |
NT-pro BNP, pg/ml | 1059.0 (515.0—2575.0) | / | / |
hs-cTnT, ng/L | 22.4 (13.4—45.8) | / | / |
Creatinine, µmol/L | 74.1 ± 17.7 | 72.4 ± 18.6 | 0.869 |
β-blocker, n (%) | 38 (76) | / | / |
LA diameter, mm | 43.8 ± 6.5 | 31.3 ± 4.7 | 0.013 |
LA volume index, ml/ m2 | 34.6 ± 12.8 | 25.7 ± 7.1 | < 0.001 |
E/e’ | 21.6 ± 8.0 | 13.6 ± 11.7 | 0.008 |
Maximum wall thickness, mm | 21.5 (19.8—25.0) | 9.1 ± 1.8 | < 0.001 |
LV mass index, g/m2 | 109.5 ± 35.7 | 68.5 ± 10.4 | < 0.001 |
Resting LVOT gradient, mmHg | 56.0 (9.0—82.0) | 7.8 ± 1.6 | < 0.001 |
Systolic anterior motion, n (%) | 29 (58) | / | / |
Pulmonary artery, mm | 22 (21—25) | 20.8 ± 2.3 | 0.003 |
PASP, mmHga | 33 (26—40) (n = 23) | / | / |
Cardiac output, L/min | 6.57 ± 2.40 | 5.56 ± 1.72 | 0.022 |
LVEF, % | 72.7 ± 6.1 | 64.3 ± 6.4 | 0.084 |
Chest pain, n (%) | 24 (48) | / | / |
Heart failure, n (%) | 41 (82) | / | / |